| |
Newsroom /
Medical
/
Medical
/
Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016
Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016
The Muscular Dystrophy Market is Forecast to Grow at a Compound Annual Growth Rate (CAGR) of 3.8% from 2009 to 2016
Hyderabad,
AP,
India
(prbd.net)
12/03/2010
"Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016"
The global muscular dystrophy market was valued at $115m in 2009 and is forecast to grow by 3.8% annually for the next seven years to reach $150m in 2016. This increase is primarily due to the increase in the diagnosis rate that translated into an increased prescription rate. In addition, the gradual increase in the cost of the drugs in this market has supported the market’s growth in the past. The market is forecast to grow because of further increases in the diagnosis rate due to the introduction of new and more efficient diagnostics techniques.
The market contains no approved products for the treatment of muscular dystrophy. Currently, Prednisone and Deflazacort are the most commonly used corticosteroids to treat the disease. The corticosteroids that have anti-inflammatory properties can delay the process of muscular atrophy. In addition to steroid therapy, patients are treated with physical and occupational therapies. Although, the three therapies – drugs, physical, occupational – are not curative, they are employed by medical practitioners to treat the disease.
The developmental pipeline for the disease contains 26 molecules. Only five of these are in Phase III and the rest are in the early stages of development. The pipeline consists of new chemical entities, biologics and gene therapy. Wyeth’s pipeline candidate MYO-029 is a myostatin inhibitor that was expected to be a disease modifying drug. However, in 2008 the drug’s clinical trails were terminated due to its lack of efficacy in arresting muscular atrophy.
At present, the muscular dystrophy market is highly underserved by the treatment options. The level of unmet need is estimated to be high. It is estimated that the 90% of the market is unsatisfied with the current treatment options. The unmet need for muscular dystrophy was estimated to be worth $103.5m in 2009. The current treatment options such as steroid therapy, physical therapy and occupational therapy do not cure the disease. Thus the current treatment options have left a significant market for new entrants. Any new entrant with better efficacy will capture a lot of value in the market.
GlobalData, the industry analysis specialist, has released its latest research “Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016”. The report provides the key data, information and analysis on the global muscular dystrophy disease market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The report provides coverage of the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need and commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among pipeline molecules, as well as an insight into the most promising pipeline drugs supplemented with key company profiles.
Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|